Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Select Drug Profiles
Select Drug Profiles
,
Payers' Guide
Xeljanz: A New Treatment Option for Patients with Rheumatoid Arthritis
Alice Goodman, Medical Writer
Read More
Select Drug Profiles
,
Payers' Guide
Tudorza Pressair: A Novel Oral Inhalation Therapy for the Maintenance Treatment of Chronic Obstructive Pulmonary Disease–Associated Bronchospasm
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Vascepa: First EPA-Only Omega-3 Therapy Approved by the FDA for Severe Hypertriglyceridemia
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Zaltrap: A New Option for the Treatment of Patients with Metastatic Colorectal Cancer Resistant to or Progressing After an Oxaliplatin-Containing Regimen
Lynne Lederman, PhD, Medical Writer
Read More
Select Drug Profiles
,
Payers' Guide
Zytiga Receives an Expanded Indication for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Zioptan Receives FDA Approval for Patients with Open-Angle Glaucoma and/or Ocular Hypertension
Loretta Fala
Read More
FDA Approvals
,
Select Drug Profiles
Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
,
Select Drug Profiles
Kadcyla (Ado-Trastuzumab Emtansine): First Antibody-Drug Conjugate Approved for the Treatment of HER2-Positive Metastatic Breast Cancer
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
,
Select Drug Profiles
Simbrinza (Brinzolamide/Brimonidine Tartrate) Receives FDA Approval for the Treatment of Open-Angle Glaucoma or Ocular Hypertension
Loretta Fala
Read More
FDA Approvals
,
Select Drug Profiles
Ilaris (Canakinumab) Receives a New Indication for the Treatment of Systemic Juvenile Idiopathic Arthritis
Lisa A. Raedler, PhD, RPh
Read More
1
2
3
4
5
Page 2 of 20
Results 11 - 20 of 200